Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
Belgium
Anima Diepenbeek ( Site 0601), Diepenbeek, Limburg Georgia
Arensia Exploartory Medicine ( Site 1301), Tbilisi Italy
Istituto Clinico Humanitas- IRCCS ( Site 1902), Rozzano, Milano Moldova
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001), Chisinau